Enhabit, Inc.
$13.80+$0.01 (+0.1%)
Last close · Data as of May 14, 2026
- Market cap
- $706.9M
- P/E
- -153.7x
- EV / EBITDA
- 20.1x
- Revenue
- $1.1B
- Net margin
- -0.4%
- ROCE
- 6.1%
Price chart
Technical chartScreen technicals →Hidden because the last close is more than three trading days older than the latest prices of its class.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 14 May 2026 close.
- 1M
- Stale
- 3M
- Stale
- 6M
- Stale
- 1Y
- Stale
- 5Y
- Stale
- Hidden because the last close is more than three trading days older than the latest prices of its class.
52-week range
Day change +$0.01 (+0.1%) from $13.79 to $13.80 · Last close May 14, 2026
Best weekday to invest, historically
The same weekly amount in EHAB, bought on each weekday since 2022.
News & filings
What Enhabit filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 4.6 million US dollars in fiscal 2025.
Strengths (1)
- Free cash flow in fiscal 2025 equals 9.3% of the company's market value.
- Prices are as of 14 May 2026; price-based points are paused until newer prices arrive.
Prices to the 14 May 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services.
Read moreShow less
Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services. This segment also provides patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases; and counseling for patients and their families regarding financial, personal, and social concerns that arise from a patient's health-related problems. Its Hospice segment offers nursing care; pain and symptom management; palliative and dietary counseling; social worker visits; spiritual counseling; and family member bereavement counseling to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is headquartered in Dallas, Texas.
- Sector
- Healthcare
- Shares outstanding
- 50.7M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $706.9M
- P/E
- -153.7x
- P/B
- 1.3x
- EV / EBITDA
- 20.1x
- EV / Sales
- 1.1x
- P/S
- 0.7x
- 52-week high
- $14.09
- 52-week low
- $6.52
Profitability
- Operating margin
- 6.0%
- Net margin
- -0.4%
- EBITDA margin
- 5.5%
- ROE
- -0.9%
- ROCE
- 6.1%
- ROIC
- 2.3%
- ROA
- -0.4%
- Asset turnover
- 0.91
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.1B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 2.4%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -0.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -97.1%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $65.8M
Solvency
- Current ratio
- 1.63
- Debt / Equity
- 0.94
- Debt / Assets
- 0.43
- CFO / Net profit
- -15.37
- Cash / Market cap
- 6.2%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $1.1B |
| Cost of revenue | $540.2M |
| Gross profit | $519.8M |
| Operating expenses | $456.0M |
| Selling, general and administrative | $433.5M |
| Operating income | $63.8M |
| Interest and other | -$62.4M |
| Pretax income | $1.4M |
| Tax and other | $6.0M |
| Net income | -$4.6M |
Revenue and net profit
Revenue grew 2.4% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $1.1B | -$40.4M |
| FY2023 | $1.0B | -$80.5M |
| FY2024 | $1.0B | -$156.2M |
| FY2025 | $1.1B | -$4.6M |
Cash flows
FY2025: $70.7M from operations, $65.8M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $80.1M | $73.0M |
| FY2023 | $48.4M | $44.9M |
| FY2024 | $51.2M | $47.4M |
| FY2025 | $70.7M | $65.8M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.1B+2.4%1Y
- EBITDA
- $57.9M
- Net profit
- -$4.6M
- Cash from operations
- $70.7M+38.1%1Y
- Free cash flow
- $65.8M+38.8%1Y
- Revenue CAGR, 3Y
- -0.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.1B | $57.9M | -$4.6M | $65.8M | -0.9% | +2.4% | -97.1% |
Monthly returns
Month-by-month returns of EHAB across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.2B |
| Current assets | $205.6M |
| Non-current assets | $961.5M |
| Liabilities | $603.0M |
| Current liabilities | $126.3M |
| Non-current liabilities | $476.7M |
| Equity | $564.1M |
| Paid-in capital | $443.6M |
| Retained earnings | $93.7M |
| Treasury stock | $3.8M |
| Minority interest | $30.1M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; EHAB highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Bright Minds Biosciences Inc., Solid Biosciences Inc., Allogene Therapeutics, Inc., Aura Biosciences, Inc., Candel Therapeutics, Inc., Design Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Enhabit, Inc.EHABthis company | $706.9M | -153.7x | 1.3x | -0.9% | 20.1x |
| HealthStream, Inc.HSTM | $738.9M | 40.3x | 2.1x | 5.2% | 11.3x |
| Bright Minds Biosciences Inc.DRUG | $731.0M | -59.8x | 8.9x | -14.9% | -46.8x |
| Solid Biosciences Inc.SLDB | $712.8M | -4.1x | 4.0x | -96.8% | -3.8x |
| CBLLCBLL | $711.4M | -13.3x | 4.6x | -34.4% | -13.8x |
| Allogene Therapeutics, Inc.ALLO | $704.1M | -3.7x | 2.4x | -65.3% | -4.1x |
| Aura Biosciences, Inc.AURA | $703.0M | -6.6x | 5.1x | -77.6% | -5.9x |
| Candel Therapeutics, Inc.CADL | $679.2M | -17.8x | 13.1x | -73.5% | -17.3x |
| Design Therapeutics, Inc.DSGN | $672.0M | -9.6x | 3.2x | -32.8% | -8.3x |
| Peer median | — | -8.1x | 4.3x | -49.8% | -7.1x |
Year-to-date ROI
EHAB since 1 January, against earlier years.
Historical volatility
EHAB's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 9.1% |
| FY2023 | 3.7% |
| FY2024 | 4.5% |
| FY2025 | 6.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.1B |
| Cost of revenueCost Of Revenue | $540.2M |
| Gross profitGross Profit | $519.8M |
| Operating expensesOperating Expense | $456.0M |
| Selling, general and administrativeSelling General And Administration | $433.5M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $22.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $22.5M |
| Total expensesTotal Expenses | $996.2M |
| Operating incomeOperating Income | $63.8M |
| Interest and other | |
| Pretax incomePretax Income | $1.4M |
| TaxTax Provision | $4.0M |
| Net incomeNet Income | -$4.6M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.2B |
| Current assetsCurrent Assets | $205.6M |
| Non-current assetsTotal Non Current Assets | $961.5M |
| LiabilitiesTotal Liabilities Net Minority Interest | $603.0M |
| Current liabilitiesCurrent Liabilities | $126.3M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $476.7M |
| EquityTotal Equity Gross Minority Interest | $564.1M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $70.7M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $70.7M |
| Net income, continuing operationsNet Income From Continuing Operations | -$2.6M |
| Depreciation and amortisationDepreciation And Amortization | $22.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $22.5M |
| Stock-based compensationStock Based Compensation | $16.6M |
| Deferred taxDeferred Tax | $0.00 |
| Deferred income taxDeferred Income Tax | $0.00 |
| Operating gains and lossesOperating Gains Losses | -$19.2M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$19.2M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | — |
| Asset impairmentAsset Impairment Charge | $47.7M |
| Change in working capitalChange In Working Capital | $3.8M |
| Other non-cash itemsOther Non Cash Items | $1.9M |
| Dividend received (operating)Dividend Received Cfo | — |
| Investing cash flowInvesting Cash Flow | $16.7M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $16.7M |
| Capital expenditureCapital Expenditure | -$4.9M |
| Capital expenditure (reported)Capital Expenditure Reported | — |
| Purchase of PP&EPurchase Of PPE | -$4.9M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$4.9M |
| AcquisitionsPurchase Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Sale of investmentsSale Of Investment | $21.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | $21.0M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | $600.0k |
| Financing cash flowFinancing Cash Flow | -$72.2M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$72.2M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | -$67.7M |
| Net debt issuedNet Issuance Payments Of Debt | -$67.7M |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$67.7M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$67.7M |
| Dividends paidCash Dividends Paid | — |
| Common dividends paidCommon Stock Dividend Paid | — |
| Other financing chargesNet Other Financing Charges | -$4.5M |
| Change in cashChanges In Cash | $15.2M |
| Cash at the start of the yearBeginning Cash Position | $30.3M |
| Cash at the end of the yearEnd Cash Position | $45.5M |
| Free cash flowFree Cash Flow | $65.8M |
| Supplemental |
Learn while you research
Academy chapters picked for Enhabit, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read